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Abstract
Chronic pain and itch are common hypersensitivity syndromes that are affected by endogenous 
mediators. We applied a systems-based, translational approach to predict, discover, and 
characterize mediators of pain and itch that are regulated by diet and inflammation. Profiling of 
tissue-specific precursor abundance and biosynthetic gene expression predicted that inflamed skin 
would be abundant in four previously unknown 11-hydroxy-epoxy-or 11-keto-epoxy-
octadecenoate linoleic acid derivatives and four previously identified 9- or 13-hydroxy-epoxy- or 
9- or 13-keto-epoxy-octadecenoate linoleic acid derivatives. All of these mediators were confirmed 
to be abundant in rat and human skin by mass spectrometry. However, only the two 11-hydroxy-
epoxy-octadecenoates sensitized rat dorsal root ganglion neurons to release more calcitonin gene–
related peptide (CGRP), which is involved in pain transmission, in response to low pH (which 
mimics an inflammatory state) or capsaicin (which activates ion channels involved in nociception). 
The two 11-hydroxy-epoxy-octadecenoates share a 3-hydroxy-Z-pentenyl-E-epoxide moiety, thus 
suggesting that this substructure could mediate nociceptor sensitization. In rats, intradermal hind 
paw injection of 11-hydroxy-12,13-trans-epoxy-(9Z)-octadecenoate elicited C-fiber–mediated 
sensitivity to thermal pain. In a randomized trial testing adjunctive strategies to manage refractory 
chronic headaches, reducing the dietary intake of linoleic acid was associated with decreases in 
plasma 11-hydroxy-12,13-trans-epoxy-(9Z)-octadecenoate, which correlated with clinical pain 
reduction. Human psoriatic skin had 30-fold higher 9-keto-12,13-trans-epoxy-(10E)-octadecenoate 
compared to control skin, and intradermal injection of this compound induced itch-related 
scratching behavior in mice. Collectively, these findings define a family of endogenous mediators 
with potential roles in pain and itch.
INTRODUCTION
Chronic pain and itch are common sources of personal suffering, disability, and societal 
expense (1–3). Current treatments often provide only partial or transient relief and have 
substantial side effects (4–8). The discovery of previously unknown endogenous mediators 
and mechanisms underlying pain and itch is needed to facilitate the development of targeted, 
effective, and safer interventions.
As the largest sensory organ, the skin is richly innervated by cutaneous nerve endings that 
can sense the microenvironment (4). Linoleic acid, the most abundant polyunsaturated fatty 
acid in the skin (5), is an “essential fatty acid” because a small amount (about 0.5% of 
energy) is needed in the diet to form the outer waxy epidermal barrier that prevents 
transepidermal water loss (6–8). Because itch and pain are common manifestations of 
cutaneous inflammatory conditions (3, 9) and linoleic acid is an endogenous substrate for 
conversion to bioactive lipid mediators (10), linoleic acid–derived mediators could be used 
to modulate cutaneous itch and pain.
We have previously shown in rats that increasing dietary linoleic acid increases linoleic acid 
derivatives in a dose-dependent manner in many tissues including the skin (11). A small 
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human trial has found correlations between a low–linoleic acid diet intervention and 
decreased headache pain (12, 13) and between reductions in circulating linoleic acid and 
pain relief, suggesting that linoleic acid–derived mediators might contribute to sensory 
signaling. However, the specific derivatives of linoleic acid that mediate or modulate 
sensation and the molecular pathways involved in their biosynthesis and signaling are 
incompletely understood.
Here, we hypothesized that previously unknown linoleic acid–derived autacoids that are 
abundant in the skin may play a role in the genesis of pain and itch. This hypothesis was 
investigated by applying a systems-based, translational approach in rats and humans to (i) 
predict previously unknown lipid mediators based on tissue-specific precursor abundance 
and transcriptomic profiling of biosynthetic genes, (ii) synthesize predicted compounds by 
total chemical synthesis, (iii) identify and quantitate these mediators in rat and human 
tissues using liquid chromatography–tandem mass spectrometry (LC-MS/MS), (iv) 
determine whether the abundance of these compounds could be altered by diet and by a 
chronic inflammatory state, and (v) examine the algesic and pruritogenic activities of these 
lipids using ex vivo sensory neuronal cultures and in vivo behavioral testing. This approach 
allowed us to identify previously unknown linoleic acid–derived lipid mediators with 
potential roles in inflammatory skin disorders, pruritus, and nociception.
RESULTS
Predicting mediators based on precursor abundance and biosynthetic gene expression 
profiles
Precursor fatty acid compositions and RNA sequencing (RNA-seq) gene expression profiles 
of nociceptive (pain) circuit tissues were used to guide the prediction of previously unknown 
lipid mediators based on the biosynthetic pathway depicted in Fig. 1A. Linoleic acid was the 
most abundant polyunsaturated fatty acid in rat skin and sciatic nerve, accounting for 27.4 
and 24.6% of total fatty acids, respectively (Fig. 1B). Linoleic acid was less abundant in 
sensory ganglia and in dorsal spinal cord.
ALOX12B and ALOX15B genes, which encode enzymes that oxidize polyunsaturated fatty 
acids containing a 1,4-cis,cis-pentadiene system (14, 15), were abundantly expressed in 
human skin (Fig. 1C); Alox12b, but not Alox15b, was also well expressed in rat skin (Fig. 
1D). ALOX15B was modestly expressed in human tibial nerve and dorsal root ganglia 
(DRG) but expressed to a lesser extent or absent in rat neural tissues comprising the 
nociceptive circuit (namely, sciatic nerve, DRG, and spinal cord dorsal horn). The ALOXE3 
gene, which encodes an enzyme that isomerizes fatty acid hydroperoxides to form specific 
hydroxy-and keto-epoxide derivatives (16), was also abundantly expressed in rat and human 
skin but less abundantly expressed or absent in peripheral nerves, sensory ganglia, and 
dorsal cord. The CYP2S1 gene, which encodes another enzyme that isomerizes fatty acid 
hydroperoxides (17), was abundantly expressed in rat skin and, especially, sciatic nerve but 
expressed to a lesser extent or absent in human pain circuit tissues. Together, these precursor 
abundance and biosynthetic gene expression profiles were used to predict previously 
unknown lipid mediators.
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Tissue-specific distributions of hydroxy-epoxy- and keto-epoxy-octadecenoates
On the basis of the high concentrations of linoleic acid and the moderate-to-high expression 
of genes encoding the biosynthetic enzymes noted above (Fig. 1), we predicted 
thattwopreviouslyunknown11-hydroxy-trans-epoxy-octadecenoates [11-hydroxy-12,13-
trans-epoxy-(9Z)-octadecenoate (11H-12,13E-LA) and 11-hydroxy-9,10-trans-epoxy-(12Z)-
octadecenoate (11H-9,10E-LA)], two previously unknown 11-keto-trans-epoxy-
octadecenoates [11-keto-12,13-trans-epoxy-(9Z)-octadecenoate (11K-12,13E-LA) and 11-
keto-9,10-trans-epoxy-(12Z)-octadecenoate(11K-9,10E-LA)], and four previously identified 
9- or 13-hydroxy- or 9- or 13-keto-trans-epoxy-octadecenoates [9-hydroxy-12,13-trans-
epoxy-(10E)-octadecenoate (9H-12,13E-LA), 13-hydroxy-9,10-trans-epoxy-(11E)-
octadecenoate (13H-9,10E-LA), 9-keto-12,13-trans-epoxy-10E-octadecenoate (9K-12,13E-
LA), and 13-keto-9,10-trans-epoxy-11E-octadecenoate (13K-9,10E-LA)] would be abundant 
in human and rat skin.
After total chemical synthesis of these eight linoleic acid derivatives for use as authentic 
standards (figs. S1 and S2, A to H), we used LC-MS/MS to quantify these mediators in rat 
and human tissues. Five of the eight mediators were present in rat skin but not in rat dorsal 
horn (table S1), indicating tissue specificity in accordance with our predictions (Fig. 1). All 
eight mediators were detected in human skin (table S2); seven of these eight mediators were 
confirmed by matching the ion spectra of the authentic standards and human skin extracts at 
characteristic retention times (fig. S2).
Increased abundance of free mediators in inflamed psoriatic human skin
Psoriatic lesions exhibited higher expression of genes coding for lipase-mediated 
release(PLA2G2AandPLA2G2F), enzymatic peroxidation (ALOX12B), and hydro-peroxide 
isomerization (CYP2S1), compared to nonlesional psoriatic skin (Fig. 2A). Thus, increases 
in both local biosynthesis and release of esterified, preformed lipids could potentially 
contribute to the higher concentrations of hydroxy-epoxy- and keto-epoxy-octadecenoates 
observed in psoriatic lesions.
In human psoriatic skin lesions and nonpsoriatic control skin, we measured these mediators 
in both the nonesterified (free) and total (sum of free plus esterified) lipid fractions. There 
were no significant differences between psoriatic skin lesions and control skin in the total 
lipid fraction (table S2). However, six of the mediators (11H-12,13E-LA, 11H-9,10E-LA, 
11K-9,10E-LA, 9H-12,13E-LA, 9K-12,13E-LA, and 13H-9,10E-LA) were markedly 
increased as free acids (the bio-active pool) in psoriatic lesions compared to control skin. 
The concentrations of free 11H-12,13E-LA and 9K-12,13E-LA were >6-fold and >30-fold 
higher in psoriatic lesions compared to control skin, respectively. The highest concentrations 
occurred in the lesions of psoriasis patients who reported itch (Fig. 2B).
The percentage of each mediator that was present as a bioavailable free acid differed 
according to the mediator. In control human skin, the percentage as free acid ranged from 
0.05% for 13H-9,10E-LA to 44.4% for 11H-12,13E-LA. In psoriatic skin lesions, the 
percentage as free acid was significantly higher than control skin for 11H-12,13E-LA, 
11K-9,10E-LA, 9K-12,13E-LA, and 13H-9,10E-LA (table S3). These findings support the 
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hypothesis that there is increased enzymatic synthesis and/or release of these free acids from 
esterified lipids in chronic epidermal inflammation.
To determine whether measurements obtained from the circulating blood could provide 
surrogate markers of skin inflammation, we next quantified these mediators in serum from 
psoriatic patients and nonpsoriatic controls. Unlike the skin, the serum concentrations of 
these eight mediators did not differ by disease status (table S4).
Stimulation of rat sensory neurons by linoleic acid derivatives
The release of calcitonin gene–related peptide (CGRP) by sensory neurons is implicated in 
the pathophysiology of numerous pain disorders (18, 19). The classic nociceptive mediator 
prostaglandin E2 (PGE2) does not significantly alter CGRP release at 1 μM concentrations at 
neutral pH (20, 21); however, PGE2 augments CGRP release evoked by low pH (which 
mimics an inflammatory state) or capsaicin (which activates ion channels involved in 
nociception) (20, 21), indicating DRG sensitization. To determine whether these linoleic 
acid derivatives sensitize DRG neurons, we tested each mediator in adult rat DRGs using a 
CGRP release assay, with PGE2 serving as a positive control. At neutral pH, neither PGE2 
nor any of the other tested compounds directly stimulated CGRP release (fig. S3, A and B). 
However,11H-12,13E-LAand11H-9,10E-LAsignificantly increased both low pH–evoked and 
capsaicin-evoked CGRP release. 13H-9,10E-LA significantly increased CGRP release at low 
pH but not in response to capsaicin. Neither 9H-12,13E-LA nor any of the tested keto-
epoxy-octadecenoates augmented low pH–evoked or capsaicin-evoked CGRP release (Fig. 
3, A to C). These observations indicate that octadecenoate-induced sensitization was 
regioselective, with the most robust effects observed for compounds containing both a 
hydroxyl group at carbon 11 and an adjacent epoxide group. These two compounds share a 
3-hydroxy-Z-pentenyl-E-epoxide moiety, identifying this substructure as a possible 
pharmacophore that mediates nociceptor sensitization (Fig. 3D).
Pain- and itch-related behaviors in rodents after intradermal injection of mediators
We next tested behavioral pain responses after intradermal injections of 11H-12,13E-LA 
because it was abundant as a free acid in inflamed human skin and augmented capsaicin and 
pH-stimulated CGRP release in rat sensory neurons. For these experiments, we compared 
the effects of the linoleic acid derivatives to vehicle and to the classic inflammatory mediator 
PGE2, which served as a positive control. After injection, C-fiber withdrawal latencies were 
decreased by 28 and 46% for 11H-12,13E-LA and PGE2, respectively, indicating 
nociceptive hyper-sensitivity (Fig. 4A). Intradermal injection of PGE2, but not 11H-12,13E-
LA, also significantly enhanced the proportion of withdrawal responses after stimulation 
with a laser tuned to selectively excite Aδ sensory neuron fibers by generating a high rate of 
heating (Fig. 4B).
Next, to examine the effects of these eight mediators on itch, we used a mouse model 
quantifying itch-related scratching bouts over the first 30 min after intradermal injection into 
the nape of the neck. We observed that 9K-12,13E-LA, but not 13K-9,10E-LA, induced itch-
related scratching behavior (Fig. 4C). Injection of a combination of 9K-12,13E-LA and 
13K-9,10E-LA also significantly increased scratching behavior compared to vehicle but to 
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the same degree as observed with 9K-12,13E-LA alone. Scratching responses evoked by 
9K-12,13E-LA had a slower onset and more gradual tapering than those observed for 
histamine (Fig. 4, D to G), with the maximal responses observed at the 100-μg dose (Fig. 
4H). Scratching responses evoked by 9K-12,13E-LA were comparable in wild-type and mast 
cell knockout (c-Kit mutant) mice (Fig. 4I). Together with our results showing that 
9K-12,13E-LA was exclusively increased in psoriatic lesional skin of those with itch (Fig. 
2B), these behavioral findings suggest that 9K-12,13E-LA may represent a novel itch 
mediator.
Regulation of mediators by dietary linoleic acid and correlation with clinical pain reduction
Next, to determine whether these mediators can be decreased by lowering the amount of 
their precursor linoleic acid in the diet, we used plasma samples from a completed 
randomized clinical trial testing a 12-week linoleic acid–lowering diet in patients with 
severe chronic daily headache (CDH) (12). We observed that five of these eight mediators 
were present in plasma (Fig. 5A). Two mediators—11H-12,13E-LA and 13H-9,10E-LA—
were significantly decreased by the linoleic acid–lowering intervention; the sum of the four 
hydroxy-epoxide-octadecenoates was reduced by 41% (Fig. 5A).
Moreover, we observed that diet-induced reductions in one of these mediators (11H-12,13E-
LA), but not the others, were closely correlated with decreases in headache hours per day 
(Fig. 5B) and headache days per month (Fig. 5C). Each SD decrease in 11H-12,13E-LA was 
associated with 25 and 11% decreases in headache hours per day and headache days per 
month, respectively (Fig. 5D). Reduction in 11H-12,13E-LA also tended to correlate with 
improvements in overall headache impact (Fig. 5D) and physical function but was not 
related to psychological distress (table S5).
DISCUSSION
Here, we applied an interdisciplinary, translational approach in rodents and humans to 
discover and characterize a new family of endogenous lipid mediators of pain and itch. On 
the basis of our own findings and previous reports indicating that the skin is enriched in both 
linoleic acid and enzymes capable of peroxidation and hydro-peroxide isomerization, we 
predicted that the skin would have high concentrations of four previously unknown 
endogenous 11-hydroxy-trans-epoxy- or 11-keto-trans-epoxy-octadecenoates and four 
previously identified 9- or 13-hydroxy- or 9- or 13-keto-trans-epoxy-octadecenoates. As 
predicted, we measured substantial concentrations of 11H-12,13E-LA, 11H-9,10E-LA, 
11K-12,13E-LA, and 11K-9,10E-LA in human skin. Notably, 11H-12,13E-LA was 
increased in inflamed psoriatic human skin, sensitized primary afferent DRG neurons in ex 
vivo CGRP release assays, and induced C-fiber–mediated pain-related hypersensitivity in 
rats. Moreover, plasma 11H-12,13E-LA correlated with headache frequency and impact in 
humans and was reduced by lowering the amount of its precursor linoleic acid in diet. In 
aggregate, these findings suggest that 11H-12,13E-LA could potentially be a mediator of 
pain modulated by diet and inflammation. 11H-9,10E-LA, which shares a 3-hydroxy-Z-
pentenyl-E-epoxide moiety with 11H-12,13E-LA, was also increased in inflamed human 
skin and sensitized rat sensory neurons, suggesting that it might also contribute to 
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inflammation-related sensitization. Our findings also confirm the presence of previously 
identified hydroxy-epoxy- and keto-epoxy-octadecenoates in human skin and provide 
insights into their potential biological actions (5, 8, 14, 15, 22–25). Consistent with previous 
findings, we observed relatively high concentrations of 13H-9,10E-LA in rodent and human 
skin (23, 24). In humans, 13H-9,10E-LA was found almost exclusively in the esterified lipid 
pool (table S3), but concentrations of free 13H-9,10E-LAwereninefold higher in psoriatic 
lesions as compared to control skin. Together with our finding that 13H-9,10E-LA 
augmented sensory neuron CGRP release in a low-pH environment, higher concentrations of 
this free acid in psoriatic skin suggest that it could potentially contribute to the 
hypersensitivity that accompanies cutaneous inflammation.
Another key finding reported here is the identification of 9K-12,13E-LA as an endogenous 
pruritogen that was increased in psoriatic lesions from patients who reported chronic itch but 
was not increased in lesions without itch. 9K-12,13E-LA has previously been detected in 
human plasma (26). In control human skin, >99% of 9K-12,13E-LA was in the esterified 
lipid fraction. The 30-fold higher concentration of 9K-12,13E-LA in the free fatty acid pool 
of psoriatic lesions compared to control skin suggests that 9K-12,13E-LA could potentially 
act as a signaling molecule in cutaneous inflammation. Consistent with this notion, we 
observed that injection of free 9K-12,13E-LA into mouse dermis caused mast cell–
independent, itch-related scratching behavior. Because 9K-12,13E-LA is enriched in 
esterified skin lipids, preformed 9K-12,13E-LA can be released by lipases to directly 
stimulate pruritus, obviating the need for de novo biosynthesis. In this regard, we detected 
high expression of PLAG2A and PLAG2F in rat skin and especially inflamed human skin 
that could serve the relevant lipase function. Future studies are needed to delineate the 
specific molecular mechanisms and receptors mediating the pruritogenic properties of 
9K-12,13E-LA.
We previously demonstrated in rats (11) that increasing dietary linoleic acid markedly 
increased the abundance of linoleic acid and its oxidized derivatives [for example, 
hydroxyoctadecadienoates (HODEs)] in tissues associated with idiopathic pain syndromes, 
including the skin. Moreover, in a trial involving 67 patients with chronic headaches, a 
linoleic acid–lowering dietary intervention decreased headache pain (12), and decreases in 
circulating linoleic acid were associated with clinical pain reduction (27), suggesting that 
linoleic acid or its derivatives could potentially contribute to pain in humans. Here, our 
finding that diet-induced reduction in circulating 11H-12,13E-LA was closely correlated 
with clinical pain reduction raises the possibility that high linoleic acid intakes could 
contribute to a biochemical susceptibility to develop chronic pain, in part by increasing the 
abundance of hydroxy-epoxy- and keto-epoxy-octadecenoates. Future trials are needed to 
determine whether lowering dietary linoleic acid can reduce these compounds in other 
tissues more directly implicated in nociception and to confirm whether such changes 
decrease chronic pain.
The current report introduces new mediators to the growing field of lipid mediators of pain 
and itch (10, 12, 28–33). Most of the work in this field has focused on mediators derived 
from arachidonic acid (34–36). Because linoleic acid is more abundant than arachidonic acid 
and other polyunsaturated fatty acids in the skin and epithelial tissues (11) and is also a 
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substrate for enzymatic conversion to oxidized mediators (14, 15), linoleic acid–derived 
mediators may be uniquely positioned to regulate nociceptive and pruriceptive responses in 
these tissues. Patwardhan et al. (28, 30) have previously implicated HODEs and other well-
known oxidized linoleic acid derivatives in peripheral and central nervous system 
nociceptive responses. In vivo cutaneous inflammatory responses are characterized by low 
pH and concurrent increases in numerous lipid and nonlipid mediators, which, together, are 
implicated in inflammation-associated hypersensitivity (4, 37). Under these conditions, 
HODEs could potentially be converted by cytochrome P-450 epoxygenases or lipoxygenases 
to form 9H-12,13E-LA, 13H-9,10E-LA, and other bioactive linoleic acid–derived mediators. 
Future studies are needed to determine which mediators or combinations are most 
responsible for the observed nociceptive responses.
This study has several important limitations. Because each of these eight linoleic acid 
derivatives was synthesized as a racemic mixture, future studies are needed to determine the 
tissue distributions and actions of individual stereoisomers. These compounds could 
potentially be converted in vivo to trihydroxyoctadecenoates (24) and dihydroxy-keto-
octadecenoates; future studies are needed to determine whether some of the observed effects 
are due to these mediators. It is also important to point out that although higher 
concentrations of these compounds were observed in chronic psoriatic lesions, we used 
acute rodent behavioral testing models to assess their effects. Additional studies using 
infusions or repeated injections may be informative to assess the effects of chronic exposure 
to these mediators. Finally, future studies are needed to determine the specific cell types, 
receptors, and signaling pathways responsible for the actions of these mediators and to 
determine whether the effects differ by species or sex. These findings define a new family of 
endogenous lipid mediators regulated by diet and chronic inflammation and provide proof of 
concept for this systems-based, translational approach for discovering new lipid mediators of 
itch and pain.
MATERIALS AND METHODS
Sample preparation and data acquisition
Clinical sample preparation, rodent behavioral testing, ex vivo CGRP release assays, and all 
laboratory analyses were performed by investigators who were blinded to clinical data and 
treatment groups.
Data analysis
Normally distributed data were expressed as means ± SE and compared using Student’s t 
test (two groups) or one-way ANOVA (multiple groups), with corrections for multiple 
comparisons as described in figure and table legends. Data that were not normally 
distributed were expressed as median and interquartile ranges and compared using Wilcoxon 
rank-sum test (two groups) and Kruskal-Wallis test (multiple groups), with corrections for 
multiple comparisons as described in figure and table legends. P < 0.05 when adjusted for 
multiple comparisons was considered significant.
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Rat tissue collection
The rat tissues analyzed in this study were obtained under protocols approved by the 
Institutional Animal Care and Use Committees of the National Institute of Dental and 
Craniofacial Research and the Clinical Center, National Institutes of Health (NIH). Male 
Sprague-Dawley rats were housed in pairs and given access to Rodent NIH-31M modified 
formula chow (Zeigler) and water ad libitum. To obtain hind paw, sciatic nerve, DRG, 
trigeminal ganglia, and dorsal horn tissue, rats were anesthetized with isoflurane and 
decapitated, and tissues were immediately dissected. Sections of the plantar surface of the 
hind paw were collected using a scalpel. Sciatic nerves were dissected starting from just 
distal to the sciatic notch and extending to just above the sciatic trifurcation. L4 and L5 
DRGs were removed after laminectomy. The spinal cord was ejected from the vertebral 
column by hydraulic force using a syringe and Hanks’ balanced salt solution, and the left 
and right dorsal quadrants were isolated. Tissues were frozen immediately on dry ice and 
stored at −80°C until processed. Rat DRG and sciatic nerve RNA-seq data are available 
under project PRJNA313202 in the Sequence Read Archive (SRA) database (38).
Precursor fatty acid analysis of rat pain circuit tissues
Tissue fatty acids were analyzed as previously described (11). Briefly, samples were thawed, 
weighed, and homogenized in butylated hydroxytoluene (BHT)/methanol for fatty acid 
extraction according to the method of Folch et al. (39). BHT was added in methanol to 
reduce lipid oxidation during the procedures. The internal standard methyl tricosanoate 
(23:0) was added to each sample. This was followed by methylation with 14% BF3/
methanol. The hexane extracts were concentrated to a small volume with a stream of 
nitrogen and transferred to microvials for gas chromatography (GC) analysis. Fatty acid 
methyl esters were analyzed with an HP-7890A GC equipped with a flame ionization 
detector (Hewlett-Packard) and a fused silica capillary column [DB-FFAP; 15 m × 0.100 
mm (internal diameter) × 0.10 μm (film thickness), J&W Scientific]. The detector and 
injector temperatures were set to 250°C. The oven temperature program began at 150°C for 
0.25 min and increased to 200°C at a rate of 10°C/min, then to 225°C at a rate of 3.5°C/min 
for 0.5 min, and finally increased to 245°C at a rate of 40°C/min, with a final hold for 15 
min. Hydrogen was used as carrier gas at a linear velocity of 50 cm/s. A custom-mixed, 30-
component, quantitative methyl ester standard containing 10 to 24 carbons and 0 to 6 double 
bonds was used to assign retention times and to ensure accurate quantification (Nu-Chek 
Prep 462). Fatty acid data were expressed as percentage of total peak area, which 
corresponded to weight % to within 5%, as demonstrated by quantitative standard mixtures. 
Internal standards were used to calculate tissue fatty acid concentrations. Fatty acid data 
were expressed as percentage of total fatty acids (%FA).
Collection of tissue and RNA purification for RNA-seq analyses
Four human L3 DRGs (three females and one male) were purchased from AnaBios from 
four different normal organ donors. Detailed information about these donors has been 
previously described (38, 40). Three female human medullary dorsal horn samples were 
collected at the level of the pyramidal decussation, and gray matter of the dorsal horn was 
isolated from fresh tissue by dissection as part of the collection procedure from the National 
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Institute of Mental Health Human Brain Collection Core as described in (40). Rat and 
human samples were homogenized in QIAzol reagent (Qiagen Inc.) using a FastPrep-24 
homogenizer (MP Biomedicals) or using a Polytron homogenizer (IKA) and purified using 
the RNeasy Mini Kit (Qiagen Inc.) with deoxyribonuclease digestion. RNA integrity number 
(RIN) was assessed after gel electrophoresis using an Agilent Bioanalyzer (Agilent 
Technologies). For rat tissues, samples with a RIN above 8.5 were sequenced. For human 
DRGs, samples with a RIN above 7 were sequenced. For other human samples, the highest 
possible RIN was obtained. The lowest sample included in this study was 5.5.
Alignment and quantification of RNA-seq count data
Rat RNA-seq data were aligned by STAR (version 2.4.2a) (41) using the rn6 genome build 
(Ensembl). Bam files resulting from this analysis were quantified using QoRTs (version 
0.3.18) (42) and converted to raw read counts and FPKM. Data from human skin of the 
lower leg (one female and seven males) and tibial nerve (six males and two females) were 
accessed by selecting eight samples of high quality (based on RIN) from the Genotype-
Tissue Expression repository. RPKM values were directly mined from data files available 
through the consortium (43). Psoriatic skin samples were accessed from the SRA database 
(PRJNA236547) (44). SRA and other human data were aligned and quantified using the 
MAGIC pipeline (45) and a genome target built in March 2016 based on RefSeq and 
AceView annotations (46). Genomic target files for MAGIC alignment are available upon 
request. Quantification and normalization of gene counts were performed by MAGIC and 
are reported in sFPKM.
Total chemical synthesis of hydroxy-epoxy- and keto-epoxy-octadecenoates
Total synthesis of each compound was performed by Cayman Chemical. Synthesized 
compounds were purified with flash chromatography and/or normal-phase high-performance 
liquid chromatography. Nuclear magnetic resonance (NMR) analysis indicated chemical 
shifts and coupling constants consistent with each chemical structure. Hydroxy-epoxy- or 
keto-epoxy-octadecenoates were analyzed by proton NMR in deuterated chloroform as their 
free acids or methyl esters as indicated (fig. S1).
Identification and quantitation of hydroxy- and keto-epoxide-octadecenoates with LC-
MS/MS
Authentic standards prepared by total synthesis were used to identify and quantitate these 
eight compounds in human and rat tissues using UPLC-MS/MS. Briefly, solid-phase 
extraction (SPE) of oxylipins from biological matrices was performed using Strata X 
cartridges (33u, 200 mg/6 ml; Phenomenex). The cartridges were conditioned with 6 ml of 
methanol, followed by 6 ml of water before samples were extracted. Samples were washed 
with 6 ml of 10% methanol. The oxylipins were eluted with 6 ml of methanol into a glass 
tube containing 10 μl of 30% glycerol in methanol. The eluate was evaporated to dryness 
under a stream of nitrogen and reconstituted with 40 μl of methanol, and an aliquot (10 μl) 
was injected into the LC-MS/MS system. A UPLC (Shimadzu Scientific Instruments) 
coupled with a QTRAP 5500 (AB Sciex) was used for qualitative and quantitative analysis. 
Briefly, separation was performed on a ZORBAX RRHD Eclipse Plus C18 column (100 mm 
× 4 mm; 1.8 μm) (Agilent Corporation) consisting of (A) 12 mM ammonium acetate 
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solution and acetic acid [100:0.02 (v/v)] and (B) 12 mM ammonium acetate and was 
composed of acetonitrile/water/acetic acid [90:10:0.02 (v/v/v)]. The flow rate was 0.5 ml/
min. The column oven temperature was set at 30°C. The elution gradient conditions were as 
follows: 25 to 40% B from 0 to 2.0 min, 40 to 46% B from 2 to 8 min, 46 to 57% B from 8 
to 9 min, 57 to 66% B from 9 to 20 min, 66 to 76% B from 20 to 22 min, 76 to 100% B from 
22 to 27 min, held at 100% B from 27 to 33 min, and 100 to 25% B from 33.1 to 35 min. 
The mass spectrometer was operated in electrospray negative ionization using scheduled 
multiple reaction monitoring (sMRM) acquiring MRM data for each analyte with a retention 
time window of 90 s. The source parameters were set as follows: ion spray voltage, −4500 
V; nebulizer gas (GS1), 65 psi; turbo gas (GS2), 70 psi; and turbo ion spray source 
temperature (TEM), 500°C. The analytes were quantified using MRM. MRM transitions, 
retention time, declustering potential, collision energy, and collision cell exit potential of 
each target analyte are listed in table S6. For hydroxy-epoxy-octadecenoates and keto-
epoxy-octadecenoates with two or three isomeric peaks in the synthesized standards (fig. 
S2), quantitation was performed by sum peak area ratios of its related peak area component/
peak area internal standard generated from Analyst 1.6.2 and plotting the best fit of total 
peak area ratios of analyte/peak area internal standard versus concentration in Microsoft 
Excel and was fitted to the equation y = ax + b. The MS/MS spectra were obtained by using 
enhanced product ion scan mode at a scan speed of 1000 Da/s. Collision-induced 
dissociation was performed using a collision energy of 35 V with a collision energy spread 
of 10. Data processing was performed using analyst software (version 1.6.2, AB Sciex). The 
identification of seven of the eight predicted compounds was confirmed by matching of the 
MS/MS spectra and retention times of endogenous linoleic acid derivatives from psoriatic 
skin samples with synthetic material using total ion mode (fig. S2).
Human studies with sample collection
Skin biopsies and serum collected from eight consecutive psoriasis participants and seven 
nonpsoriatic controls were included in the study (age range, 26 to 82 years) enrolled in an 
ongoing NIH observational study of psoriasis and cardiometabolic diseases 
(NCT01778569). The demographic and clinical characteristics of the study groups are 
shown in table S7. Study procedures were approved by the National Heart, Lung, and Blood 
Institute Institutional Review Board. All participants submitted written informed consent 
before enrollment. Briefly, a diagnosis of psoriasis was confirmed and quantified by a 
dermatologist using the Psoriasis Area Severity Index. The presence or absence of 
substantial itch was documented using a self-reported questionnaire. Corresponding controls 
were consecutively recruited to undergo the same testing as the psoriasis participants. All 
participants were free of any systemic antipsoriatic treatments or topical therapy within 2 
weeks before biopsy. At baseline, 4-mm punch biopsies were obtained under local 
anesthesia from psoriatic plaque and unaffected skin. Biopsy sites were selected on the basis 
of active plaques and varied between subjects. However, biopsies of unaffected and control 
skin were predominantly from the buttocks. Whole blood from the same participants was 
collected in serum separator tubes, centrifuged, and immediately stored at −20°C until 
analysis.
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The CDH trial was a randomized, 12-week trial designed to test the clinical and biochemical 
effects of diets low in linoleic acid (L6 intervention) with or without a concurrent increase in 
n–3 fatty acids (H3-L6 intervention) in a population with CDH. The trial was conducted at 
the University of North Carolina at Chapel Hill (UNC) from April 2009 to November 2011. 
Trial procedures were approved by the UNC Institutional Review Board, and the trial 
protocol, dietary compositions, and primary clinical and some biochemical findings were 
previously described (12, 47, 48). Briefly, adults meeting the CDH criteria of headaches >4 
hours per day and >15 days per month for at least 3 months and a headache history of >2 
years were recruited to participate. The demographic and clinical characteristics of the study 
groups are shown in table S8. Participants continued their usual physician care and were 
advised to continue taking medications as needed throughout the study. During the 4-week 
pre-intervention phase, participants continued their habitual diets and recorded headache 
characteristics in a daily headache diary. On completion of the run-in phase, participants 
were randomized to one of the two study diets, which lasted for 12 weeks. Linoleic acid was 
reduced in the study diets by restricting consumption of vegetable oils and other rich sources 
of linoleic acid and replacing them with vegetable oils and foods rich in monounsaturated 
and saturated fats. Plasma was collected at baseline and at the conclusion of the 12-week 
diet phase. We previously reported that the H3-L6 intervention produced marked reductions 
in headache frequency and severity and enhanced quality of life and function while reducing 
the use of acute pain medications (12, 13). Diet-induced changes in one or more families of 
n–6– or n–3–derived lipid autacoids likely contributed to these clinical benefits; however, 
the specific mechanisms responsible for these effects are unknown. Here, we use pre- and 
post-intervention plasma samples from this study to investigate (i) whether the study diets 
altered plasma concentrations of hydroxy- and keto-epoxide derivatives of linoleic acid 
using the Wilcoxon matched-pairs signed-rank test and (ii) whether changes in mediator 
concentrations correlated with clinical pain reduction using regression models adjusted for 
the baseline values of each outcome and mediator.
Preparation of solid tissues for LC-MS/MS analysis
Solid tissues (human skin, rat hind paw, or rat dorsal horn) were transferred into FastPrep 
Lysing Matrix tubes on ice (Lysing Matrix A for the skin and hind paw and Lysing Matrix D 
for the dorsal horn; MP Biomedicals), and at least eight times greater volume of ice-cold 
methanol with 0.02% (v/v) BHT and 0.02% (v/v) EDTA was immediately added to each 
tube. A known amount of internal standards was added to each sample, and samples were 
homogenized using a FastPrep-24 homogenizer (MP Biomedicals). Tissue homogenates 
were transferred to −80°C for 1 hour to precipitate proteins. Homogenates were centrifuged 
at 17,000g in 4°C for 10 min, and the supernatant was transferred to a new test tube. Half the 
supernatant was stored in −80°C until SPE purification and LC-MS/MS analysis (see 
above). To allow for the analysis of total lipid pools, we saponified the other half of the 
supernatant with 2.6% sodium carbonate (by weight) at 60°C for 30 min under gentle 
shaking. The solution was then neutralized (pH 5 to 7) using acetic acid and stored in −80°C 
overnight. Immediately before purification by SPE and LC-MS/MS analysis, lipid extracts 
(free and saponified total) were added to a ninefold greater volume of ice-cold water.
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Preparation of plasma and serum for LC-MS/MS analysis
Two hundred microliters of plasma or serum was transferred to 500 μl of ice-cold methanol 
with 0.02% BHT and 0.02% EDTA and transferred to −80°C to precipitate proteins (as 
described above). A known amount of internal standards was then added, samples were 
centrifuged, and the supernatant was collected as described above. The supernatant was then 
added to a ninefold greater volume of ice-cold water, purified with SPE, and analyzed by 
LC-MS/MS, as described above.
Ex vivo sensory neuron sensitization assays (CGRP release assays)
For release experiments, the work was approved by the Animal Care and Use Committee at 
the Indiana University School of Medicine, Indianapolis, IN. Adult rat sensory neuronal 
cultures were prepared as previously described (49, 50). Cells were maintained for 10 to 12 
days in F-12 medium (Invitrogen) supplemented with 10% horse serum, 2 mM glutamine, 
normocin (100 μg/ml), penicillin (50 μg/ml), streptomycin (50 μg/ml), 50 μM 5-fluoro-2′-
deoxyuridine (Invitrogen), 150 μM uridine, and nerve growth factor (30 ng/ml) (Harlan 
Bioproducts for Science Inc.) in 3% CO2 at 37°C. On the day of the release experiments, 
cultures were washed with Hepes buffer [25 mM Hepes, 135 mM NaCl, 3.5 mM KCl, 2.5 
mM CaCl2, 1 mM MgCl2, 3.3 mM D-glucose, and 0.1% bovine serum albumin (pH 7.4)] 
and maintained at 37°C. Cultures were then incubated with 0.4 ml of the same buffer in the 
absence or presence of drugs. Basal release was determined by exposing the cells to Hepes 
buffer alone for 10 min and then to buffer in the presence of mediators for 10 min to 
ascertain whether the compounds stimulated release. Cultures were then exposed to buffer 
containing 10 nM capsaicin or buffer with the pH adjusted to 6.0 in the absence or presence 
of mediators. Cells were then re-exposed to Hepes buffer without drugs for a 10-min 
incubation to reestablish basal release. After each incubation, the buffer was removed to 
measure the amount of CGRP using radio-immunoassay as previously described (51). At the 
end of each release experiment, cells were hypotonically lysed by exposing the cultures to 
0.1 M HCl for 10 min and an aliquot was taken to measure total CGRP content in the 
cultures using radioimmunoassay. Release data are presented in femtomoles per well of cell 
per 10 min from three independent experiments from separate harvests. Statistical analysis 
was performed using ANOVA with Tukey’s post hoc test.
Rodent behavioral assays
To analyze pruriceptive (itch) behavior, we intradermally injected hydroxy-and keto-epoxide 
derivatives of linoleic acid (100 μg) or histamine (50 μg) into the nape of the neck of the 
mice (C57BL/6J and c-Kit mast cell–deficient mice, both from the Jackson Laboratory). 
Linoleic acid derivatives (9K-12,13E-LA or 13K-9,10E-LA) were injected independently 
and in combination [9K-12,13E-LA plus 13K-9,10E-LA (100 μg of each)] except in the c-
Kit study in which 9K-12,13E-LA was injected alone. Pruriceptive behavior was quantified 
as the number of scratching bouts assessed over 30 min, as previously described (52). For 
the dose-response study, we injected 0, 50, 100, or 200 μg of 9K-12,13E-LA in 20 μl of 
vehicle and counted scratching bouts for 30 min.
To analyze nociceptive (pain) behavior, we intradermally injected 11H-12,13E-LA (30 μg) 
into the hind paw of male Sprague-Dawley rats. Baseline measurements were taken for all 
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tests before injection. Aδ fiber– and C-fiber–mediated hind paw withdrawal responses were 
measured as previously described (53) by the delivery of thermal stimuli using a 980-nm 
infrared diode laser with a visible guide beam (LASS-10 M, Lasmed). Aδ fibers were 
selectively activated using a 100-ms 1.6-mm heat pulse that generates a high rate of heating 
(54). This stimulation paradigm results in a fast reflex response that was scored for intensity 
using a previously validated scale (55). Briefly, 1 is a simple withdrawal, 2 is a repeated 
tapping of the paw, 3 is orienting toward the paw, and 4 is a paw lick. C-fiber–mediated 
responses were measured after the delivery of a 5-mm-diameter slow temperature ramp by 
using a lower-intensity heating beam (53, 55).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Proposed molecular pathways: precursor fatty acids and expression of genes coding for 
enzymes involved in biosynthesis of mediators in pain circuit tissues
(A) Proposed biosynthetic pathways include lipase-mediated release of esterified linoleic 
acid (LA), lipoxygenase-mediated peroxidation, and hydroperoxide isomerization. (B) The 
abundance of precursor fatty acids in rat tissues (n = 4 rats for each tissue). (C and D) 
Quantitative biosynthetic gene expression in human (C) (n = 8, 8, 4, and 3 for the skin, tibial 
nerve, DRG, and dorsal cord, respectively) and rat (D) (n = 3, 4, 8, and 6 rats for hind paw, 
sciatic nerve, DRG, and dorsal cord, respectively) pain circuit tissues. Box plots and error 
bars in (B) to (D) indicate means and SEM. AA, arachidonic acid; DHA, docosahexaenoic 
acid; PLA2, phospholipase A2; Alox, lipoxygenase; Cyp, cytochrome P-450 epoxygenase; 
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HpODE, hydroperoxyoctadecadienoate; sFPKM, standard fragments per kilobase of 
transcript per million mapped reads.
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Fig. 2. Free hydroxy-epoxy- and keto-epoxy-octadecenoates are increased in human psoriatic 
skin lesions in participants reporting itch
(A) Expression of genes coding the phospholipases, ALOX12B and CYP2S1 enzymes in 
human psoriatic skin lesions compared to nonlesional psoriatic skin (n = 10 participants per 
group). (B) Concentrations of free hydroxy-epoxy- and keto-epoxy-octadecenoates in 
psoriatic lesions compared to control human skin. Statistical analysis was performed using 
the Kruskal-Wallis test [n = 7, 3, and 5 participant specimens for control skin, psoriasis 
lesion (no itch), and psoriasis lesion (itch), respectively].
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Fig. 3. Regioselective augmentation of CGRP release from adult rat DRG neurons
(A to C) Ex vivo CGRP release measured from adult rat DRG neuronal cultures in response 
to low pH (A and B) or capsaicin (C) [n = 9 wells (A) or 12 wells (B and C), each from three 
separate harvests]. (D) The shared 3-hydroxy-Z-pentenyl-E-epoxide moiety that is unique to 
these two lipids is the proposed pharmacophore mediating the effects of 11H-12,13E-LA 
and 11H-9,10E-LA. *P < 0.05 using analysis of variance (ANOVA) with Tukey’s post hoc 
test.
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Fig. 4. Pain- and itch-related rodent behavior responses after intradermal injections
(A and B) C-fiber withdrawal latency responses (A) and Aδ fiber stimulation responses after 
injection of mediators or vehicle control (B) (30 μg per injection; n = 12, 11, and 10 rats for 
vehicle, 11H-12,13E-LA, and PGE2, respectively). (C) Scratching bouts after injection of 
mediators (100 μg per mediator; n = 8, 7, 6, and 8 mice for vehicle, 9K-12,13E-LA, 
13K-9,10E-LA, and the mixture, respectively). (D and E) Time course of scratching 
responses (D) and cumulative scratching bouts (E) evoked by the various mediators. (F and 
G) Time course (F) and scratching responses and cumulative scratching bouts (G) evoked by 
histamine (50 μg; n = 6 mice each for histamine and control). (H) Dose response for 
scratching bouts after injection of 9K-12,13E-LA (n = 6 mice for each dose). (I) Cumulative 
scratching bouts after injection of 9K-12,13E-LA in wild-type compared to c-Kit mutant 
Ramsden et al. Page 22
Sci Signal. Author manuscript; available in PMC 2018 February 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
mice (n = 5 and 8 for wild-type and c-Kit mutant mice, respectively). C-fiber withdrawal 
responses were compared using one-way ANOVA followed by Dunnett’s multiple 
comparisons test. Aδ pain ratings and itch responses were analyzed by Kruskal-Wallis test 
followed by Dunn’s multiple comparisons test. Time course itch-related scratching data (D 
to G) were analyzed by two-way repeated-measures ANOVA followed by Dunnett’s 
multiple comparison test to compare each treatment at each time point. *P < 0.05, **P < 
0.01.
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Fig. 5. Association between diet-induced changes in plasma linoleic acid derivatives and pain-
related end points in the CDH trial
(A) Changes in plasma concentrations of individual and total hydroxy-epoxy-octadecenoates 
(H-E-LA) after decreased dietary intake of linoleic acid for 12 weeks in patients with CDH 
(n = 44 participants). Red dashed lines indicate the limit of quantitation; P values based on 
Wilcoxon matched-pairs signed-rank test. (B to D) Associations between diet-induced 
reductions in plasma hydroxy-epoxy-octadecenoate concentrations and headache hours per 
day (B) (n = 40 participants), headache days per month (C) (n = 44 participants), and 
headache impact (D) (n = 44 participants). Graphs include the headache outcomes (y axes) 
compared to the mediator concentrations at week 12 (x axis) based on a Poisson regression 
model controlling for each outcome and mediator concentration at baseline. 95% confidence 
intervals are shown in blue.
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